Clinical And Experimental Immunology

杂志介绍

Clinical And Experimental Immunology杂志介绍

《Clinical And Experimental Immunology》是一本以English为主的未开放获取国际优秀期刊，中文名称临床和实验免疫学，本刊主要出版、报道医学-IMMUNOLOGY领域的研究动态以及在该领域取得的各方面的经验和科研成果，介绍该领域有关本专业的最新进展，探讨行业发展的思路和方法，以促进学术信息交流，提高行业发展。该刊已被国际权威数据库SCIE收录，为该领域相关学科的发展起到了良好的推动作用，也得到了本专业人员的广泛认可。该刊最新影响因子为3.4，最新CiteScore 指数为8.4。

本刊近期中国学者发表的论文主要有：

• New insights of antineutrophil cytoplasmic antibody-associated vasculitis from the perspective of COVID-19 vaccination

  Author: Yang, Yang; Xiong, Yi; Xu, Gaosi

• Signals from the TAFA4-PTEN-PU.1 axis alleviate nasal allergy by modulating the expression of Fc epsilon RI in mast cells

  Author: Zhou, Caijie; Li, Meihua; Liu, Yu; Wang, Xinxin; Zhang, Shuang; Guan, Li; Hong, Jingyi; Zhou, Wei; Wu, Gaohui; Diao, Weiliang; Huang, Qinmiao; Yang, Pingchang

• Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis

  Author: Zhao, Shaoli; Zhou, Yulu; Sun, Wei; Li, Zuojun; Wang, Chunjiang

• HTNV infection induces activation and deficiency of CD8(+)MAIT cells in HFRS patients

  Author: Zhang, Yusi; Wang, Meng; Zhang, Xiyue; Tang, Kang; Zhang, Chunmei; Jia, Xiaozhou; Hu, Haifeng; Liu, He; Li, Na; Zhuang, Ran; Jin, Boquan; Ma, Ying; Zhang, Yun

英文介绍

Clinical And Experimental Immunology杂志英文介绍

Clinical & Experimental Immunology (established in 1966) is an authoritative international journal publishing high-quality research studies in translational and clinical immunology that have the potential to transform our understanding of the immunopathology of human disease and/or change clinical practice.

The journal is focused on translational and clinical immunology and is among the foremost journals in this field, attracting high-quality papers from across the world. Translation is viewed as a process of applying ideas, insights and discoveries generated through scientific studies to the treatment, prevention or diagnosis of human disease. Clinical immunology has evolved as a field to encompass the application of state-of-the-art technologies such as next-generation sequencing, metagenomics and high-dimensional phenotyping to understand mechanisms that govern the outcomes of clinical trials.